Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

New England Journal of Medicine

Volumn 362, Issue 14, 2010, Pages 1273-1281

  Valle, Juan ^a   Wasan, Harpreet ^b   Palmer, Daniel H ^e   Cunningham, David ^c   Anthoney, Alan ^f   Maraveyas, Anthony ^g   Madhusudan, Srinivasan ^h   Iveson, Tim ⁱ   Hughes, Sharon ^d   Pereira, Stephen P ^d   Roughton, Michael ^d   Bridgewater, John ^d  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f Leeds   (United Kingdom)

^g CASTLE HILL HOSPITAL   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FATIGUE; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; KAPLAN MEIER METHOD; KIDNEY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME; VATER PAPILLA CARCINOMA; VOMITING;

EID: 77950822827     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0908721     Document Type: Article

References (22)

1. UK National Statistics home page. (Accessed March 12, 2010, at http://www .statistics.gov.uk.)
2. Patel T. Incieasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357
3. Jamagin WR, Fong Y, DeMatteo RP, et aL Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517
4. Glimelius B, Hoffman K, Sjodén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
5. Rao S, Cunningham D, Hawkins RE, et aL Phase III study of 5FU, etoposide and leucovorin (FFXV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:1650-1654
6. Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005;41:398-403.
7. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofblinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001;19:4089-4091
8. Komek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase n trial. Ann Oncol 2004;15:478-483
9. Crinó L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15:297-303.
10. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608
11. Hitt R, Castellano D, Hidalgo M, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1998;9: 1347-1349
12. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study -the UK ABC-01 Study. Br J Cancer 2009;101:621-627
13. Scher HI, Heller G. Picking the winners in a sea of plenty. Clin Cancer Res 2002;8:400-404
14. Therasse P, Arbuck SG, Eisenhauer EA, et aL New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
15. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-530
16. Dingle BH, Rumble RB, Brouwers MC. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 2005;19:711-716
17. Furuse J, Miyazaki M, Taniai H, Nimura Y. A randomized study of gemcitabine/ cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. J Clin Oncol 2009;27:Suppl:15s. abstract.
18. Malka D, Trarbach T, Fartoux L, et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO triaL J Clin Oncol 2009; 27:Suppl:15s. abstract.
19. Ortner MEJ, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003, 125:1355-1363
20. Pfitzner J. Poiseuille and his law. Anaesthesia 1976;31:273-275
21. Hansel DE, Rahman A, Hidalgo M, et aL Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 2003; 163:217-229
22. Tannapfel A, Som merer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-712